Mouse IgG_2a Fc Muted™ (LALA-PG), Isotype Control – Purified No Carrier Protein

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day Ambient

This isotype control antibody should be used at the same concentration as the primary antibody.

This Mouse IgG2a (Anti-KLH) isotype control antibody has been tested against selected species' cells and tissues to assure minimal cross reactivity. This antibody was chosen as an isotype control after screening on a variety of resting, activated, live, and fixed mouse, rat and human tissue.

In this Fc Muted™ format, mutations (LALA-PG) have been introduced at crucial binding sites of the Fc domain with the FcR and C1q, reducing or eliminating Fc-mediated Antibody Dependent Cellular Phagocytosis (ADCP).

1. Ikeda Y. et al. (2003) Blood.101(2):621-3. Article Link
2. Wright, TM et al. (2000) J Immunol.164(12):6138-46.PubMed
3. Wright, TM et al. (2001) Arthritis Rheum. 44(7):1654-9. PubMed
4. Nishikawa, Takeji et al. (2000) Journal of Investigative Dermatology 114(1): 88-94. PubMed